Central Precocious Puberty
Gonadotropin-releasing hormone (GnRH) agonist Triptodur treats central precocious puberty via intramuscular injection.
Data from a phase 3 clinical trial found that triptorelin achieved positive results in patients age 2 and older with central precocious puberty.
Ovarian cyst and McCune-Albright syndrome were most responsible for the increased risk of non-congenital adrenal hyperplasia gonadotropin-independent precocious puberty.
Long-term treatment with the histrelin implant safely and effectively sustained gonadotropin suppression and improved predicted adult height in central precocious puberty.
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Type 2 Diabetes Associated With Increased Fracture Risk in Postmenopausal Women
- Use of FSH in Early Diagnosis of Turner Syndrome
- Closed-Loop Insulin Delivery Offers Best Outcomes for Pregnant Women With T1D
- Surgical Treatment Better Than Medical Therapy in Severely Obese Adolescents With T2D
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome